Search Clinical Trials in the European Union

1-2 years
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
221-240 of 653 trials

Thyroid Eye Disease: Lu AG22515 Treatment

We are investigating the effects of Lu AG22515 on eye bulging in adults with moderate-to-severe Thyroid Eye Disease. This study aims to see if it can improve symptoms related to this condition.

Thyroid Eye Disease1-2 yearsSafety phase (I)16-20 visitsNo PlaceboInvestigational MedicinesCost ReimbursementEndocrinologyOphthalmology

Frontotemporal Dementia: DNL593 Study

We are evaluating the safety and tolerability of a new drug, DNL593, in healthy individuals and those with frontotemporal dementia. This study aims to understand how the drug works in the body and its effects over time.

Frontotemporal Dementia1-2 yearsSafety phase (I)Efficacy phase (II)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementNeurology

Metastatic Colorectal and Gastroesophageal Cancer: Trifluridine/Tipiracil Study

We are studying the safety of Trifluridine/tipiracil as a new chemotherapy for patients with metastatic colorectal or gastroesophageal cancer who have a specific genetic deficiency. This trial aims to see if it can be a safer alternative to traditional treatments.

Metastatic Colon or Rectal Cancer with DPD Deficiency1-2 yearsEfficacy phase (II)No PlaceboStandard MedicinesInternal MedicineOncology

Chronic Rhinosinusitis: Lebrikizumab Study

We are testing a new medication, lebrikizumab, for people with chronic rhinosinusitis and nasal polyps who are already using nasal corticosteroids. The study aims to see if it can improve nasal congestion and reduce polyp severity.

Chronic Rhinosinusitis with Nasal Polyps1-2 yearsConfirmation phase (III)Standard MedicinesCost ReimbursementPartially RemoteOtolaryngologyPulmonology

Ulcerative Colitis and Crohn’s Disease: Vedolizumab for Kids

We are studying the long-term safety of vedolizumab in children with ulcerative colitis or Crohn’s disease. The trial also looks at how this treatment affects their quality of life and related health events.

Ulcerative ColitisCrohn's Disease1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Refractory Focal Onset Epilepsy: BHV-7000 Safety Study

We are evaluating the safety and tolerability of BHV-7000 in adults with refractory focal onset epilepsy. This study aims to ensure the treatment is safe for those who have not found relief with other options.

Focal Epilepsy1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Epidermolysis Bullosa Simplex: Diacerein 1% Ointment

We are studying a new ointment for people with generalized Epidermolysis Bullosa Simplex to see if it helps improve skin condition and reduce symptoms. The trial includes both adults and children aged 6 months and older.

Epidermolysis Bullosa Simplex1-2 yearsEfficacy phase (II)Confirmation phase (III)Post-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteDermatology

Heart Failure: Finerenone and SGLT2 Inhibitor Study

We are investigating whether a combination of finerenone and an SGLT2 inhibitor can improve health outcomes for hospitalized heart failure patients. This study aims to see if this approach leads to better symptom relief and fewer hospital visits.

Heart Failure1-2 yearsConfirmation phase (III)No PlaceboStandard MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine

Acute Vaginal Infection: BGY-1601-VT Tablet

We are studying a new vaginal tablet for women with acute vaginal infections to see if it works better than a placebo. The trial will help us understand its safety and effectiveness for conditions like Bacterial Vaginosis and Vulvovaginal Candidiasis.

Gynecological Conditions1-2 yearsSafety phase (I)Efficacy phase (II)≤5 visitsInvestigational MedicinesGynecology and ObstetricsInfectious Diseases

Hypertrophic Cardiomyopathy: Aficamten Study

We are evaluating the long-term safety and tolerability of aficamten in adults with hypertrophic cardiomyopathy. The study also looks at its effects on heart function in patients with obstructive HCM.

Hypertrophic Cardiomyopathy1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesCardiologyInternal Medicine

Cardiac Device Implantation: Local vs. Regional Anesthesia

We are comparing local anesthesia with a specific regional block to see which provides better comfort for patients undergoing cardiac device implantation. This study also looks at any side effects and the need for extra pain relief.

Implantation of Cardiac Devices1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesCardiologyInternal MedicineOtolaryngology

Vedolizumab for Children with Moderate to Severe Crohn's Disease

We are studying how well different doses of vedolizumab help children and teenagers with Crohn's disease maintain their health. The goal is to see if it can keep symptoms under control and improve their overall well-being.

Crohn's Disease1-2 yearsConfirmation phase (III)Post-Trial Drug AccessNo PlaceboStandard MedicinesCost ReimbursementGastroenterologyPediatrics

Idiopathic Pulmonary Fibrosis: Buloxibutid Study

We are testing a new medication, buloxibutid, to see if it helps improve lung function and quality of life for people with idiopathic pulmonary fibrosis. The study compares its effects to a placebo over time.

Idiopathic Pulmonary Fibrosis1-2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicinePulmonology

Septic Shock: Early Use of Vasopressin

We are studying whether starting vasopressin treatment earlier helps improve kidney function in patients with septic shock. This trial aims to see if it reduces the need for kidney support and other complications in the ICU.

Septic Shock1-2 yearsMonitoring phase (IV)No PlaceboStandard MedicinesInternal MedicineNephrologyPulmonology

Crohn's Disease: New Treatment Target Study

We are investigating if aiming for complete healing of all bowel layers improves outcomes for patients with active Crohn's disease. This study compares different treatment strategies to see which is more effective.

Crohn's Disease1-2 yearsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesGastroenterologyInternal Medicine

Primary Immune Thrombocytopenia: Belantamab Mafodotin Study

We are investigating a new treatment for adults with primary immune thrombocytopenia who have previously received other therapies. The study aims to assess the safety and effectiveness of this new drug.

Primary Immune Thrombocytopenia1-2 yearsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesHematology

Fecal Microbiome Transplantation for Decompensated Cirrhosis

We are studying whether fecal microbiome transplantation can help slow the progression of decompensated cirrhosis in patients. The trial will assess its effects on survival, complications, and overall health.

Decompensated Cirrhosis1-2 yearsConfirmation phase (III)≤5 visitsInvestigational MedicinesGastroenterologyHepatology

Parkinson's Disease: New Treatment Study

We are testing a new treatment in healthy volunteers and individuals with Parkinson's disease, including those with specific genetic mutations. This study aims to understand how the treatment works in different groups.

Parkinson's Disease1-2 yearsSafety phase (I)Neurology

Avian Influenza Vaccine: Immune Response Study

We are studying how well a new avian influenza vaccine triggers immune responses in people, especially those with prior seasonal flu vaccinations. This research aims to understand its effectiveness against various H5N1 virus strains.

Avian Influenza and Seasonal Influenza1-2 yearsMonitoring phase (IV)≤5 visitsNo PlaceboStandard MedicinesInfectious DiseasesPulmonology

Heart Attack Treatment: RTP-026 Study

We are exploring a new medication, RTP-026, for patients who have had a heart attack. The study will assess its safety and effectiveness compared to a placebo.

Heart Attack (Acute Myocardial Infarction)1-2 yearsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInternal Medicine